Literature DB >> 2139460

The murine complement receptor gene family. IV. Alternative splicing of Cr2 gene transcripts predicts two distinct gene products that share homologous domains with both human CR2 and CR1.

C B Kurtz1, E O'Toole, S M Christensen, J H Weis.   

Abstract

The murine Cr2 gene encodes at least two related proteins. The first of these is predicted to include 1408 amino acids from a transcript including 4224 coding nucleotides. This protein is predicted to contain 21 60-amino acid repeats plus those residues encoding transmembrane and cytoplasmic regions for a total peptide m.w. of 155,307. The first six of these repeats are similar to human CR1 in sequence and organization. The second protein is encoded by an alternatively spliced Cr2 transcript that is lacking those sequences which encode the first six 60-amino acid repeats of the larger protein. This second, smaller protein, encoded by a transcript of 3096 coding nucleotides, is predicted to include 15 60-amino acid repeats, plus the transmembrane and cytoplasmic regions. This smaller protein contains 1032 amino acids for a peptide m.w. of 113,328. This second protein is extremely homologous in size and sequence to human CR2. Both proteins share the same signal sequence for membrane insertion. DNA sequence analysis, RNA protection studies and genomic phage mapping indicate the transcripts which encode these proteins are derived from the Cr2 gene via alternative splicing.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2139460

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  39 in total

1.  The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a novel targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer mouse models.

Authors:  Masha Fridkis-Hareli; Michael Storek; Eran Or; Richard Altman; Suresh Katti; Fang Sun; Tao Peng; Jeff Hunter; Krista Johnson; Yi Wang; Ante S Lundberg; Gaurav Mehta; Nirmal K Banda; V Michael Holers
Journal:  Mol Immunol       Date:  2018-12-01       Impact factor: 4.407

2.  New nucleotide sequence data on the EMBL File Server.

Authors: 
Journal:  Nucleic Acids Res       Date:  1990-10-25       Impact factor: 16.971

Review 3.  Significance of MHC class II haplotypes and IgG Fc receptors in SLE.

Authors:  Sachiko Hirose; Yi Jiang; Hiroyuki Nishimura; Toshikazu Shirai
Journal:  Springer Semin Immunopathol       Date:  2006-09-14

Review 4.  Complement receptors and the shaping of the natural antibody repertoire.

Authors:  V Michael Holers
Journal:  Springer Semin Immunopathol       Date:  2004-12-22

Review 5.  Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity.

Authors:  Franklin R Toapanta; Ted M Ross
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 6.  Molecular structure and expression of anthropic, ovine, and murine forms of complement receptor type 2.

Authors:  Dong Liu; Jian-Ying Zhu; Zhong-Xiang Niu
Journal:  Clin Vaccine Immunol       Date:  2008-04-09

7.  Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2.

Authors:  H Molina; V M Holers; B Li; Y Fung; S Mariathasan; J Goellner; J Strauss-Schoenberger; R W Karr; D D Chaplin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

8.  Molecular characterization of rat Crry: widespread distribution of two alternative forms of Crry mRNA.

Authors:  R J Quigg; C F Lo; J J Alexander; A E Sneed; G Moxley
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

Review 9.  B cell acquisition of antigen in vivo.

Authors:  Santiago F Gonzalez; Lisa A Pitcher; Thorsten Mempel; Franziska Schuerpf; Michael C Carroll
Journal:  Curr Opin Immunol       Date:  2009-06-08       Impact factor: 7.486

10.  CD21 signaling via C3 regulates Purkinje cell protein 4 expression.

Authors:  Amanda C Jacobson; Janis J Weis; John H Weis
Journal:  Mol Immunol       Date:  2009-02-07       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.